Form 4: Pfizer CEO Albert Bourla Acquires Phantom Stock Units

Pfizer Chairman and CEO Albert Bourla acquired 23 phantom stock units through the company's deferred compensation plan.

Summary

• Albert Bourla, Chairman and CEO of Pfizer Inc., acquired 23 phantom stock units on May 29, 2026.
• The units were acquired under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.
• Each phantom unit represents one share of common stock and is valued at $26.18 per unit.
• Following this transaction, the reporting person holds a total of 772,789 phantom stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard executive compensation activity rather than a strategic market move.

Positives

• Continued alignment of executive interests with company performance through deferred compensation participation.

Negatives

• None identified.

Risks

• Value of phantom stock units is subject to the underlying performance of Pfizer common stock.

Future Outlook

The units are settled in cash following the reporting person's separation from service, with the option to transfer into alternative investment accounts.

Industry Context

StockSavvy.ai notes that routine acquisitions of phantom stock units via deferred compensation plans are standard executive compensation practices and do not typically signal a change in market sentiment or strategic direction.

Comparison to Industry Standards

• The transaction is consistent with standard executive compensation and retention programs utilized by large-cap pharmaceutical companies like Merck, Bristol Myers Squibb, and Eli Lilly.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine internal compensation transaction.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Pfizer, PFE, Albert Bourla, Form 4, Insider Trading, Phantom Stock